Patient guide
GLP-1 medicines for type 2 diabetes versus weight management
GLP-1 receptor agonists and tirzepatide are used both to treat type 2 diabetes and to manage weight. The products, licences, goals and NHS routes are not the same. This guide explains the differences so that you can understand which pathway you are on.
Last checked: 2026-10-03
Key facts
At a glance.
-
Different products
Some brands are licensed for diabetes and others for weight management, even where the active ingredient is the same or closely related.
-
Different goals
In diabetes the main target is glucose control and risk reduction; in weight management it is weight and related health risk.
-
Different NHS rules
Diabetes prescribing follows diabetes guidance and local formularies; weight-management prescribing follows obesity guidance.
-
Off-label use
Using a diabetes product only for weight loss in a person without diabetes is outside its licence.
Same family, different licences
Semaglutide is sold in forms with different brand names depending on the licensed use, and tirzepatide has been licensed for both type 2 diabetes and weight management under separate indications. Doses, pen strengths and titration steps can differ between the diabetes and weight-management versions. A prescriber should choose the product whose licence matches your reason for treatment.
Goals and measures of success
For type 2 diabetes the main measures are HbA1c, glucose patterns, blood pressure, cholesterol and cardiovascular and kidney risk. Weight loss is a welcome effect but not the only aim. For weight management, the key measure is percentage change in body weight alongside improvements in weight-related conditions. A person with both diabetes and obesity may benefit on both fronts.
NHS prescribing differences
In diabetes care, GP practices and diabetes teams prescribe within NICE type 2 diabetes guidance and local pathways, which consider other medicines such as metformin and SGLT2 inhibitors. For obesity, NICE guidance TA1026 and TA875 and the NG246 obesity guideline set separate eligibility rules. Being prescribed one of these medicines for diabetes does not automatically make you eligible for the weight-management indication, and vice versa.
Safety and monitoring points that differ
-
People with diabetes using insulin or sulfonylureas are at greater risk of low blood sugar when a GLP-1 medicine is added, so doses of those medicines may need reducing.
-
People with diabetic retinopathy should be monitored, because rapid glucose improvement has been associated with temporary worsening of eye disease in some studies of semaglutide.
-
Kidney function is checked more systematically in diabetes care.
-
People with obesity but no diabetes need attention to nutrition, muscle and eating behaviour.
Switching between indications
Some people start on a diabetes product and later move to a weight-management product, or the reverse. This should be a prescriber decision, not a swap done informally, because doses and funding differ. If you are given a different pen, check with the pharmacist that the dose you have been told matches the pen and product you hold.
Supply and prescribing integrity
During periods of shortage of diabetes products, regulators and NHS bodies have asked prescribers not to prescribe diabetes-licensed pens for weight loss alone, to protect supply for people who need them for glucose control. This is another reason that understanding the indication matters.
Frequently asked
Questions people ask.
Quick, plain-English answers to the questions we hear most.
-
Is Ozempic the same as Wegovy?
They contain the same active ingredient but are licensed for different uses and have different dose ranges. Your prescriber should choose the one that matches your indication.
-
Can I use a diabetes pen to lose weight?
In a person without diabetes that is outside the licence. Clinicians are advised to avoid it when it could reduce supply for people with diabetes.
-
If I have diabetes and obesity, which pathway applies?
Both may apply. Your diabetes team will decide the most appropriate product and funding route.
-
Will I need to lower my other diabetes tablets?
Possibly, especially insulin or sulfonylureas, which can cause low blood sugar. Your team will advise.
-
Does it protect the heart in diabetes?
Some products in this class have shown cardiovascular benefit in trials of people with diabetes and heart risk. Your clinician can say whether that applies to you.
-
Does my eye screening matter?
Yes. Keep diabetic eye screening appointments and tell the screening team that you have started a GLP-1 medicine.
-
What if I use insulin?
Tell your diabetes team before starting. Insulin doses often need adjustment, and hypoglycaemia advice should be reviewed.
-
Can type 2 diabetes go into remission with these medicines?
Weight loss can improve glucose control substantially, and some people reach remission. This depends on duration and weight lost, and remission can reverse.
Where this comes from
Sources and checking.
This guide is for information, not medical advice.
Your GP or consultant knows your history and can tell you which parts apply to you. If your symptoms are severe, rapidly worsening, or come with red-flag features, seek urgent medical care. Figures and availability change, so treat them as a guide and confirm with the provider.
Published 2026-10-03, next review 2027-10-03.
-
NICE guideline NG246, Overweight and obesity management (nice.org.uk)
-
NICE technology appraisal TA1026, Tirzepatide for managing overweight and obesity (nice.org.uk)
-
NICE technology appraisal TA875, Semaglutide for managing overweight and obesity (nice.org.uk)
-
MHRA drug safety updates and Yellow Card scheme information (gov.uk/mhra)
-
NHS website, Obesity and weight-loss medicines pages (nhs.uk)